[go: up one dir, main page]

MX2010002499A - Bayas del goji e inflamacion. - Google Patents

Bayas del goji e inflamacion.

Info

Publication number
MX2010002499A
MX2010002499A MX2010002499A MX2010002499A MX2010002499A MX 2010002499 A MX2010002499 A MX 2010002499A MX 2010002499 A MX2010002499 A MX 2010002499A MX 2010002499 A MX2010002499 A MX 2010002499A MX 2010002499 A MX2010002499 A MX 2010002499A
Authority
MX
Mexico
Prior art keywords
inflammation
wolfberries
relates
present
treat
Prior art date
Application number
MX2010002499A
Other languages
English (en)
Inventor
Karine Vidal
Olivier Ballevre
St Phanie Blum-Sperisen
David Philippe
Peter Bucheli
Junkuan Wang
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2010002499A publication Critical patent/MX2010002499A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invenci?n se refiere en general al campo de la inflamaci?n. En particular la presente invenci?n se refiere al uso de compuestos naturales para la preparaci?n de un producto para tratar o prevenir la inflamaci?n. Por ejemplo un extracto de baya del goji demostr? poseer propiedades anti-inflamatorias. Una modalidad de la presente invenci?n se refiere al uso de una composici?n primaria que comprende bayas del goji o una parte de lo mismo para la preparaci?n de un producto para tratar p prevenir la inflamaci?n.
MX2010002499A 2007-09-12 2008-09-12 Bayas del goji e inflamacion. MX2010002499A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116190A EP2036568A1 (en) 2007-09-12 2007-09-12 Wolfberries and inflammation
PCT/EP2008/062122 WO2009034162A1 (en) 2007-09-12 2008-09-12 Wolfberries and inflammation

Publications (1)

Publication Number Publication Date
MX2010002499A true MX2010002499A (es) 2010-04-27

Family

ID=38984201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002499A MX2010002499A (es) 2007-09-12 2008-09-12 Bayas del goji e inflamacion.

Country Status (15)

Country Link
US (2) US20100303741A1 (es)
EP (3) EP2036568A1 (es)
JP (1) JP2010540415A (es)
CN (2) CN103417728A (es)
AR (1) AR068448A1 (es)
AU (1) AU2008297074A1 (es)
BR (1) BRPI0816789A2 (es)
CA (2) CA2698860A1 (es)
CL (1) CL2008002692A1 (es)
ES (1) ES2698199T3 (es)
MX (1) MX2010002499A (es)
PT (1) PT2200624T (es)
RU (1) RU2499604C2 (es)
TW (1) TW200930389A (es)
WO (2) WO2009034165A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201021821A (en) * 2008-12-10 2010-06-16 Fl Dauern Res Inc Formulations and methods for maintaining normal levels of catecholamines, glucocorticoids, androsteroids and their related hormones
RU2532343C2 (ru) * 2009-09-02 2014-11-10 ЭКСЕСС БИЗНЕСС ГРУП ИНТЕРНЭШНЛ ЭлЭлСи Композиция и способ для восстановления кожи
WO2011079212A2 (en) * 2009-12-24 2011-06-30 LifeSpan Extension, LLC Methods and compositions for identifying, producing and using plant-derived products modulating cell function and aging
DK3366143T3 (da) 2011-06-20 2025-01-27 Heinz Co Brands H J Llc Probiotiske sammensætninger og fremgangsmåder
CN103027879A (zh) * 2011-09-29 2013-04-10 庞来祥 一种具有保湿作用的枸杞唇膏及其制备方法
CN107397830A (zh) 2012-04-23 2017-11-28 奥斯陆大学 番茄提取物用作抗高血压剂的用途以及制造水溶性无糖番茄提取物的方法
GB201223365D0 (en) 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
CN105997774A (zh) * 2016-05-10 2016-10-12 芜湖亮晶晶生物科技有限公司 一种止血消炎牙膏及其制备方法
CA3042720A1 (en) 2016-11-02 2018-05-11 Provexis Natural Products Limited Water soluble tomato extract protects against adverse effects of air pollution
CN106667937B (zh) * 2017-01-03 2020-01-17 河北省农林科学院经济作物研究所 一种黑枸杞多糖咀嚼片
US11491134B2 (en) 2019-06-20 2022-11-08 Industrial Technology Research Institute Composition for inhibiting skin cell proliferation and/or anti-inflammation method for inhibiting skin cell proliferation and/or anti-inflammation and method for treating skin diseases and/or inflammatory diseases
CN110742883A (zh) * 2019-12-05 2020-02-04 华南农业大学 二氢杨梅素在缓解呕吐毒素引起肠道细胞损伤中的应用
CN112022767B (zh) * 2020-09-17 2023-04-07 云南省药物研究所 一种抗炎抑菌增强免疫祛痘组合物及其应用
US20250049084A1 (en) * 2021-12-20 2025-02-13 Societe Des Produits Nestle S.A. Process for preparing a berry composition
CN114209810B (zh) * 2022-01-06 2023-02-07 宁夏杞肽科技有限公司 枸杞糖肽在制备用于预防或治疗炎性肠病的药物中的用途
JP7587294B2 (ja) * 2022-04-01 2024-11-20 丸善製薬株式会社 正常ヒト歯肉線維芽細胞におけるｉ型コラーゲン産生促進剤及び口腔用剤
CN118662572A (zh) * 2024-05-31 2024-09-20 北京工商大学 一种具有延缓皮肤光老化和抑制炎症功效的中华枸杞水提物制备与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100949A (zh) * 1994-03-11 1995-04-05 李启才 金樱保健系列产品及其制法
CN1135338A (zh) * 1995-05-06 1996-11-13 孙秀英 芸杞保健茶
CN1296757A (zh) * 2000-07-09 2001-05-30 鄂来明 芦荟奶制品
KR20040071764A (ko) * 2001-12-28 2004-08-12 산또리 가부시키가이샤 ２―Ｏ―（β―Ｄ―글루코피라노실）아스코르브산, 그의제조, 및 이를 함유하는 조성물 포함 식품 및 화장품
RU2302879C2 (ru) * 2002-04-09 2007-07-20 Сычуан Институте Оф Чайниз Материа Медика Фармацевтическая композиция для лечения ревматизма, способ ее приготовления и применение
TW200515914A (en) * 2002-11-08 2005-05-16 Wackvom Ltd Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
JPWO2005018656A1 (ja) * 2003-08-21 2006-10-19 株式会社カネカ 脳神経細胞死予防及び／または改善剤
EP2251008A1 (en) * 2003-12-18 2010-11-17 Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House Methods for reducing the effects of stress on skin condition
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
US20060024339A1 (en) * 2004-07-29 2006-02-02 Howard Murad Methods of managing the redness associated with a dermatological condition
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
JP2007176814A (ja) * 2005-12-27 2007-07-12 Yoshihiro Futamura 炎症性サイトカイン産生抑制作用を有するゼアキサンチン誘導体、それからなる食品製剤、化粧品、抗炎症剤

Also Published As

Publication number Publication date
CN101795699A (zh) 2010-08-04
EP2200623A1 (en) 2010-06-30
AU2008297074A1 (en) 2009-03-19
EP2036568A1 (en) 2009-03-18
AR068448A1 (es) 2009-11-18
US9072769B2 (en) 2015-07-07
ES2698199T3 (es) 2019-02-01
JP2010540415A (ja) 2010-12-24
EP2200624B1 (en) 2018-09-05
CN103417728A (zh) 2013-12-04
US20100221372A1 (en) 2010-09-02
BRPI0816789A2 (pt) 2015-03-17
HK1146229A1 (en) 2011-05-20
RU2499604C2 (ru) 2013-11-27
US20100303741A1 (en) 2010-12-02
CA2698860A1 (en) 2009-03-19
CA2699233A1 (en) 2009-03-19
CN101795699B (zh) 2013-07-10
RU2010114192A (ru) 2011-10-20
EP2200624A1 (en) 2010-06-30
WO2009034165A1 (en) 2009-03-19
CA2699233C (en) 2019-03-19
TW200930389A (en) 2009-07-16
PT2200624T (pt) 2018-11-29
WO2009034162A1 (en) 2009-03-19
CL2008002692A1 (es) 2009-10-16

Similar Documents

Publication Publication Date Title
MX2010002499A (es) Bayas del goji e inflamacion.
PH12012500894A1 (en) Benzodiazepine bromodomain inhibitor
MY146969A (en) Dpp iv inhibitor formulations
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
WO2010011296A3 (en) Deacetylase inhibitors and uses thereof
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
CA2818187C (en) Bromodomain inhibitors and uses thereof
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
PT2222294E (pt) Composições de derivados polifenólicos stilbénicos e suas aplicações para lutar contra as patologias e o envelhecimento dos organismos vivos
EP3581177A3 (en) Compositions comprising acidic extracts of mastic gum
WO2007125331A3 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
MX2015007540A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2010068815A3 (en) Compositions and methods for treating cellular proliferative disorders
WO2010030835A3 (en) Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
MX2012011382A (es) Nuevo polimero.
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
AU2012307257A8 (en) Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration